Mark Agulnik, MD, Medical Oncologist at the City of Hope speaks about Phase II study of pazopanib with oral topotecan…
Browsing: Other
Jubilee Brown, MD from the Levine Cancer Institute, and Division of Gynecologic Oncology, Atrium Health speaks about Clinical Activity and…
Eric Klein, MD from the Glickman Urological and Kidney Institute at the Cleveland Clinic speaks about Blood Test That Detects…
Denise Riedel Lewis, Ph.D. from the Division of Cancer Control and Population Sciences, National Cancer Institute speaks about the Survival…
Amy Turner, Ph.D. from the University of Leeds, The Astbury Centre, Tomlinsonlab@leeds speaks about New treatment approach targets cancer ‘Death…
Ugochi Ogu, MD, an assistant professor in the Division of Hematology and Oncology at the University of Tennessee Health Science…
Shahid Gilani, MD from the University Hospital Of North Midlands speaks about Hypofractionated radiotherapy as a definitive treatment for Basal…
Shahid Gilani, MD from the University Hospital Of North Midlands speaks about the Direct Oral Anticoagulants (DOACs) in Cancer-Related Thromboembolism.Link…
Theresa Deisher, Ph.D. from AVM Biotechnology speaks about FDA Approves Accelerated Dosing in Non-Hodgkin’s Lymphoma/Leukemia Clinical Trial.Link to Article:https://www.businesswire.com/news/home/20210713005415/en/FDA-Approves-Accelerated-Dosing-in-Non-Hodgkin%E2%80%99s-LymphomaLeukemia-Clinical-TrialThree of…
Sarbajit Mukherjee, MD, MS, Assistant Professor of Oncology in the Department of Medicine at Roswell Park Comprehensive Cancer Center speaks…
Ian Chau, MD, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust speaks about The CheckMate 648, 649, and 577…
Oliver Rosen, MD, CMO of SQZ Biotechnologies speaks about the ASCO 2021 Abstract – Initial results of a first-in-human, dose…
Tony Kurian, MD, Oncology Fellow at H. Lee Moffitt Cancer Center & Research Institute speaks about the ASCO 2021 Abstract…
Brian Van Tine, MD, Ph.D., associate professor of medical oncology, Washington University School of Medicine speaks about the ASCO 2021…
Anas Alshawa, MD from the University of Arizona speaks about the Effects Of Glutamine For Prevention Of Radiation-induced Esophagitis: A…
Michal R. Tomaszewski, Ph.D. from H. Lee Moffitt Cancer Center and Research Institute speaks about ASCO 2021 Abstract – Imaging-based…
Julian Andres Marin-Acevedo, MD from H. Lee Moffitt Cancer Center & Research Institute speaks about ASCO 2021 Abstract – Efficacy…
Abdulraheem Yacoub, MD from the University of Kansas Center for Bioinformatics speaks about ASCO 2021 Abstract – A phase 3,…
Abdulraheem Yacoub, MD from the University of Kansas Center for Bioinformatics speaks about ASCO 2021 Abstract – A phase 3,…
Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center speaks about the ASCO 2021 Abstract – Pemigatinib…
Pablo Okhuysen, MD, FACP from MD Anderson speaks about the ASCO 2021 Abstract – Impact of Cancer-Related Diarrhea on Changes…
Mingxuan Xu, Ph.D., Research Scientist at MD Anderson speaks about the Implementation of a Novel Web-Based Lesion Selection Tool to…
Murat Ak, MD from UPMC speaks about Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.Link to…
Drs. Charu Aggarwal and Jack West host dynamic GU oncology specialist Dr. Petros Grivas as they discuss how research, mentorship,…
Lenka Kyrych Sadilkova, Ph.D. from SOTIO speaks about the AACR 2021 Poster: SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting…
Thomas Brown, MD Syapseâ chief medical officer speaks about Syapse Showcases Real-World Mortality Data in American Society of Clinical Oncologyâs…
Jonathan A. Coleman, MD from Memorial Sloan Kettering Cancer Center speaks about ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial…
Eytan M. Stein, MD, Assistant Attending Physician, and Director, Program for Drug Development in Leukemia, Department of Medicine at Memorial…
Scott Loughhead, Ph.D. from SQZ Biotechnologies speaks about AACR 2021Abstract – Peripheral Blood Mononuclear Cells Engineered Via Microfluidic Cell Squeeze®…
Scott Loughhead, Ph.D. from SQZ Biotechnologies speaks about AACR 2021Abstracts – Clinical Applications Abstract Number: 2626 and Technology Abstract Number:…
Dino Mehic, MD from the Medical University of Vienna speaks about Elevated levels of tissue factor pathway inhibitor in patients…
Rona Yaeger, MD from Memorial Sloan Kettering Cancer Center speaks about KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Link to…
Valeria Arango Velez, MD, Founder, Healing Presents speaks about being This Years Astellas Oncology C3 Prize – Innovation Prize Winner.Astellas…
Jacob J. Adashek, DO University of South Florida, H. Lee Moffitt Cancer Center and Research Institute discusses the AARC 2021…
Jacob J. Adashek, DO University of South Florida, H. Lee Moffitt Cancer Center and Research Institute discusses AARC 2021 Abstract…
Dr med Florian Moik from the Medical University of Vienna, Department of Medicine I, Division of Haematology and Haemostaseology, Comprehensive…
Hosts Jack West and Charu Aggarwal speak with radiation oncology experts David Palma of the London Health Sciences Centre and…
Satish Shah, MD, Medical Director, Gettysburg Cancer Center speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial…
Omolola Salako, MBBS, FWACS, Founder and CEO, Oncopadi Technologies speaks about the Astellas Oncology C3 Prize – This Years Grand…
Tito R. Mendoza, Ph.D., MS, MEd from The University of Texas MD Anderson Cancer Center speaks about Associations between the…
Lisa McKenzie, Founder, and Executive Producer, You Night Empowering Events speaks about being This Years Astellas Oncology C3 Prize -…
Allison W. Kurian, MD, MSc from Stanford University California speaks about Genetic Testing for Breast and Ovarian Cancer: What Has…
What is the C3 Prizeâ„¢? Â Cancer is a difficult disease to understand. Astellas Oncology acknowledges the complexity of the…
Richard T. Lee, MD from Case Western Reserve University speaks about Familiarity With Complementary and Integrative Therapies Among Patients With…
Lucas W. Thornblade, MD, MPH of the City of Hope speaks about Patterns of Whole Genome Sequencing and Actionable Mutations…
Christopher I. Amos, Ph.D. from the Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine speaks…
Ethan Basch, MD, MSc from the Lineberger Comprehensive Cancer Center, University of North Carolina speaks about the Benefits of Digital…
Robert Zeiser, MD from the University Medical Center Freiburg, speaks about Incyte Announces Acceptance and Priority Review of sNDA for…
Mehmet Asim Bilen, MD from Winship Cancer Institute of Emory University discusses the Evaluation of a novel blood pressure scoring…
Takeo Fujii, MD, MPH from MD Anderson Cancer Center speaks about the Incidence of immune-related adverse events and its association…
Roy S. Herbst, MD, Ph.D., chief of Medical Oncology at Yale University discusses the IASLC 2020 abstract – Lung-Map Translational…
Pasi A. Jänne, MD, Ph.D. from Dana-Farber Cancer Institute discusses Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer…
Crystal Denlinger, MD of the Fox Chase Cancer Center discusses Crystal Denlinger Named Chief Scientific Officer for National Comprehensive Cancer…
Grzegorz S. Nowakowski, MD from the Mayo Clinic speaks about the Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly…
Conor E. Steuer, MD from the Winship Cancer Institute of Emory University in Atlanta discusses Patients with Lung Cancer Reduce…
Erminia Massarelli, MD Ph.D. from the City of Hope speaks about Lung Cancer: Her Experience, Research, And The Current Treatment…
Uri Ben-David, Ph.D. Assistant Professor, Department of Human Molecular Genetics and Biochemistry at the Tel Aviv University speaks about the…
Gypsyamber D’Souza, Ph.D. from Johns Hopkins, Bloomberg School of Public Health speaks about Timing, number, and type of sexual partners…
Guillermo Garcia-Manero, MD from The University of Texas MD Anderson Cancer Center speaks about ASH 2020 Abstract – 1230 Clinical…
Andreana N. Holowatyj, Ph.D., MS Assistant Professor of Medicine and Cancer Biology from Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center…
Nathan Connell, MD, MPH, FACP of Brigham and Women’s Hospital, Harvard Medical School speaks about ASH ISTH NHF WFH 2021…
Aung Naing, MD, FACP of MD Anderson discusses the Phase 2 study of pembrolizumab in patients with advanced rare cancers.InstractContext:There…
Omar M. Abdel-Rahman Abdelsalam, MBBCh, MSc, MD, Assistant Professor of Medical Oncology from the University of Alberta discusses the New…
Aung Naing, MD, FACP MD Anderson speaks about Strategies for improving the management of immune-related adverse events.You can download the…
R. Stephanie Huang, Ph.D. of the University of Minnesota and R.S. Huang Lab discusses Computationally predicting clinical drug combination efficacy…
Ron Peck, MD, Chief Medical Officer of Arvinas speaks about Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential…
Javid Moslehi, MD and Justin M. Balko, Pharm.D., Ph.D. from Vanderbilt-Ingram Cancer Center discuss A genetic mouse model recapitulates immune…
Gelareh Zadeh, M.D., Ph.D., FRCS(C), FAANS, professor and dan chair of Neurosurgery at the University of Toronto, head of the…
Robert Zeiser, MD of the University Medical Center, Freiburg Im Breisgau discusses the ASH abstract – 77 Ruxolitinib (RUX) Vs…
Steven W. Pipe, MD of the University of Michigan, Ann Arbor speaks about ASH 2020 abstract – Gene Therapy for…
Clint Valentine, MS from TwinStrand Biosciences discusses TwinStrand Biosciences Announces Peer-Reviewed Publication of Study Results Highlighting Ability of Duplex Sequencing…
Jyoti Nangalia, MBBChir of the Wellcome Sanger Institute, Hinxton, United Kingdom, University of Cambridge, Wellcome-MRC Cambridge Stem Cell Institute, Cambridge,…
Mukta Arora, MD, PI and Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota speaks about the…
Brian Van Tine, MD, Ph.D. of Washington University of School of Medicine, in St. Louis speaks about Spearhead 1 Study…
John Mascarenhas, MD of the Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute speaks about the ASH 2020…
John Mascarenhas, MD of the Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute speaks about the ASH 2020…
Douglas Blayney, MD, Professor of Medicine (Oncology) of Stanford University Medical Center discusses the SABCS 2020 abstract – The Timing…
Kimberly C Jenkins, MSNM from the Cleveland Clinic discusses the ASH 2020 abstract – 3441 Increased Productivity and Efficiency Among…
Naveen Pemmaraju, MD of MD Anderson speaks about Blastic Plasmacytoid Dendritic Cell Neoplasm.ContextNatural killer (NK) cell leukemia/lymphoma was historically identified…
Lee Zuckerman, MD Orthopedic Surgeon at the City of Hope, a comprehensive cancer center near Los Angeles discusses Use of…
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Anthony Yanni, M.D., Senior Vice President, patient-centricity at…
Klaus Hoeflich, Ph.D. Senior Vice President, Biology at Blueprint Medicines Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust…
Natasha Leighl, MD Princess Margaret Cancer Centre speaks on the press release Liquid biopsies timely and effective testing method for…
Vishruta A. Dumane, Ph.D., Assistant Professor Radiation Oncology of the Icahn School of Medicine at Mount Sinai speaks about the…
Erin Murphy, MD of the Cleveland Clinic discusses the ASTRO 2020 Abstract 2546 Safety of Metastasis-Directed SBRT and Concurrent Pazopanib…
Gregory M. Videtic MD, CM, FRCPC, FACR, FASTRO Section Head for Thoracic Malignancies and Residency Program Director in the Department…
Kunal Sindhu, MD from the Icahn School of Medicine at Mount Sinai speaks about the ASTRO 2020 Abstract 3009 Identifying…
Robert Coleman, MD, FACOG, FACS, Chief Scientific Officer U.S. Oncology Research discusses Elevation Oncology and US Oncology Research Announce Collaboration…
John R. “Jack†Steel, M.D. F.A.C.R.O. of Tampa Bay Radiation Oncology discusses Managing Anxiety During Cancer Treatment. Some of the…
Abby Westerman, founder of b-present Foundation – Astellas discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award…
Andy Krivoshik, MD, Ph.D. – Astellas Oncology discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award the…
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…
Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Tim Blauwkamp, Ph.D., Chief Scientific Officer and co-founder…
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib…
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib…
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and…
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and…
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and…
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib…
Lipika Goyal, MD of Massachusetts General Hospital @MassGeneralNews discusses the data for futibatinib in advanced intrahepatic cholangiocarcinoma. Read here:Â https://www.prnewswire.com/news-releases/taiho-oncology-announces-presentation-of-data-for-futibatinib-in-advanced-intrahepatic-cholangiocarcinoma-at-2020-asco-meeting-301068213.html?tc=eml_cleartime
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term…
Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses CX-2029, a PROBODY drug conjugate targeting CD71: Results from a…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1)…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1)…
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.
Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.
Andrew Krivoshik, MD of Astellas @AstellasUS discusses what is net for Astellas.
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy…
Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research
Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research
Nicholas Vogelzang, MD of Comprehensive Cancer Center @CCCNevada discusses the single arm, phase 2, TRITON2 clinical trial supported FDA approval…
Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed…
Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed…
Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85% of newly…
Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.
Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally…
Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Fumito Ito, MD, PhD of Roswell Park @RoswellPark discusses CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with…
Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with…
Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read…
Adilia Hormigo, MD of Mount Sinai Health System @MountSinaiNYC discusses the clinical study of the safety and tolerability of laser…
Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and…
Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research and Jonathan Pachter, PhD of Verastem Oncology discuss the new…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a…
Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways:…
Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways.…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways.…
Earn CME: https://www.naccme.com/program/19-cpc-101-7 This webcast features a presentation by Dr. Gary H. Lyman that examines the potential benefits of incorporating…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews addresses how the randomized phase IIB trial of proton beam therapy versus intensity-modulated…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews answers if this can be extended to the community on the randomized phase…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews discusses the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses fundamental mechanism for other clinical outcomes and phenotypes. ___________ In a new Cleveland…
Moleculin Biotech, Inc., (Nasdaq:Â MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the implications of real-world…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence)…
Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics,…
ACE1702 is a potential off-the-shelf cell therapy developed using Acepodia’s Antibody-Cell Conjugation technology Acepodia, a biotechnology company developing cancer immunotherapy…
John Mascarenhas, MD of @MountSinaiNYC discusses MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi)
Richard Sainson, PhD @rcasainson of @kymabltd answers KY1044, targets ICOS increasing cytotoxic to regulatory T cells ratio: how does this…
Richard Sainson, PhD @rcasainson of @KymabLtd explains KY1044, targets ICOS increasing cytotoxic to regulatory T cells ratio: what mechanism of…
Richard Sainson, PhD @rcasainson of @kymabltd shares Kymab’s new findings for KY1044 presented at the #CICON2019 annual meeting.
Nicklas Oscarsson of @goteborgsuni on how oxygen in hyperbaric chamber provides relief after radiotherapy affects clinicians and treatment today. ________…
Nicklas Oscarsson of @goteborgsuni answers frequently asked questions regarding oxygen in hyperbaric chamber provides relief after radiotherapy. __________ Hyperbaric oxygen…
Nicklas Oscarsson of @goteborgsuni explains oxygen in hyperbaric chamber provides relief after radiotherapy. ___________ Hyperbaric oxygen therapy (HBOT) in the…
Greg Delgoffe, PhD @delgoffelab of @PittTweet explains how the dual-function virus designed to killing tumors is affecting clinicians today. ________…
Greg Delgoffe, PhD @delgoffelab of @PittTweet explains the dual-function virus designed to killing tumors and helping immune cells. __________ Viruses…
Cancer center recognized for following best practices in field Designated centers demonstrate best practices outlined by NCCN, ACR Roswell Park’s…
Kristin Campbell of @UBCnews shares exercise guidelines for cancer survivors. ________ There is growing evidence that exercise is a significant…
Kristin Campbell of @UBCnews explains exercise guidelines for cancer survivors limitations and safety concerns. __________ There is growing evidence that…
There is growing evidence that exercise is a significant part of recovery for the increasing number of cancer survivors worldwide.…
James Suliburk, MD @jsuliburk of @bcmhouston answers how far away is this technology from being used in clinical practice? ___________…
James Suliburk, MD @jsuliburk of @bcmhouston explains new tests for thyroid cancer could prevent unnecessary surgery. ___________ Read here:Â https://www.eurekalert.org/pub_releases/2019-10/uota-ntf100219.php
Amanda Haymond of @GeorgeMasonNews @GMU_COS explains a new discovery that includes protein painting technology and enables scientists to make discoveries…
Valérie Gabarre @valeriegabarre of @OSEIMMUNO discusses the ATALANTE-1 trial and the TEDOPaM study presented by OSE Immunotherapeutics at #ESMO19. __________…
Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel…
Hypertension with ibrutinib more common than previously reported; this study is first to show association between cancer drug-related hypertension and…
William Smith, MD of Mount Sinai addresses the next steps in radiation therapy on the objective response and outcomes in…
William Smith, MD of Mount Sinai explains how this affects clinicians today? _______ Among patients with unresectable hepatocellular carcinoma who…
William Smith, MD of Mount Sinai answers multiple questions received from colleagues, including: when did patients receive radiation relevant to…
William Smith, MD of Mount Sinai describes the effect of radiation therapy on the objective response and outcomes with nivolumab…
A recent analysis from Canada found that information on health-related quality of life is often not collected for investigational cancer…
-Â DKN-01 Monotherapy Patient with an Ongoing Complete Response -Â Enhanced PFS in patients with Wnt Activating Mutations and DKK1-high Tumors CAMBRIDGE,…
Dr. Erin Murphy, MD of Cleveland Clinic provides insight on how this will affect clinicians today. _____ Preoperative (neoadjuvant) stereotactic…
Dr. Erin Murphy, MD of Cleveland Clinic answers a question received form colleagues: why dose escalation? _____ Preoperative (neoadjuvant) stereotactic…
Dr. Erin Murphy, MD of Cleveland Clinic explains the phase I dose escalation study for neoadjuvant radiosurgery for large brain…
State-of-the-art AI algorithms applied to digitised images of oral cancer tissue specimens can be used to predict their chances of…
– 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
Richard S. Finn MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California offers his…
Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the…
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center shares the next step for hepatocellular carcinoma (HCC)…
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center discusses the outcomes of KEYNOTE-240 which compares pembrolizumab…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses the design differences between ENZAMET and TITAN…
Read the full transcription HERE: http://bit.ly/MarkCubanEonExpertSeries A discussion with Mark Cuban and three leading Pulmonologists regarding problems in healthcare technology…
On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the…
Gratitude is one of the most medicinal emotions we can feel. (Sara Avant Stover) Thank you for joining GRACE in…
Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines…
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and…